Immunic (NASDAQ:IMUX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research report report published on Friday.

Separately, Brookline Capital Management reissued a buy rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, April 5th.

Immunic Stock Up 4.2 %

NASDAQ:IMUX opened at $1.23 on Friday. The company has a market capitalization of $110.61 million, a PE ratio of -0.58 and a beta of 2.07. The stock has a fifty day simple moving average of $1.33 and a 200-day simple moving average of $1.26. Immunic has a 52-week low of $0.95 and a 52-week high of $3.11.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, February 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. As a group, equities analysts anticipate that Immunic will post -0.99 earnings per share for the current year.

Hedge Funds Weigh In On Immunic

Several hedge funds and other institutional investors have recently modified their holdings of IMUX. Innovis Asset Management LLC increased its stake in shares of Immunic by 46.3% in the 3rd quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock valued at $401,000 after buying an additional 86,217 shares during the period. Acadian Asset Management LLC lifted its holdings in Immunic by 26.8% during the third quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock worth $1,111,000 after acquiring an additional 159,973 shares in the last quarter. RTW Investments LP lifted its holdings in Immunic by 0.9% during the third quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after acquiring an additional 40,796 shares in the last quarter. Sweet Financial Partners LLC bought a new position in Immunic during the fourth quarter worth about $45,000. Finally, Gratus Capital LLC lifted its holdings in Immunic by 15.1% during the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after acquiring an additional 254,999 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.